Life Science Leader — April 2013 Outsourcing and the oral solid dose: Will challenges lead to new patterns of outsourcing? Life Science Leader — CRO Leadership Awards supplement issue Strategic Outsourcing Often Means Combining Functional and Full-Service CROs 
 
May 10 Life Science Leader's May issue includes results from Nice Insight annual research April 10 Learn about Trends in Outsourcing the Oral Solid Dose in April's Outsourcing Insights 
"Nice Insight’s thought-provoking data gave me new insight into existing
companies that outsource research and manufacturing services and products."
Director of Chemical Product R&D, Specialty Pharmaceutical Company, North America  
BioProcess International Conference
September 16-20 Boston, MA |
Covance Inc. ICON plc Lupin Pharmaceuticals, Inc. Siegfried Aptalis Pharmaceutical Technologies
Aptalis Pharmaceutical Technologies (formerly Eurand Pharmaceutical Technologies) specializes in product development based on proprietary pharmaceutical technologies. It partners with customers to develop prescription and OTC products that offer advantages over existing therapies or address unmet medical needs – and also offers production and licensing of commercial products. Integrated R&D and manufacturing teams in the U.S. and Europe support projects from formulation through scale-up to commercial-scale manufacturing, with multiple sites supporting distribution worldwide. Aptalis Pharmaceutical Technologies has one of the broadest ranges of pharmaceutical technology platforms in the industry, including taste masking, customized drug release, and bioavailability enhancement. It has developed products currently marketed in 50 countries around the world and an in-licensed patent portfolio that consists of over 900 patents and pending applications. http://www.aptalispharmaceuticaltechnologies.com
Regions
Americas, Europe Stock Symbol Private Filter of Aptalis Pharmaceutical Technologies's services per Nice Insight Categories
Contact Aptalis Pharmaceutical Technologies 
|
|
|
